平均毛利率大幅升至49.2% 中国先锋医药(01345.HK)中期纯利达9820万元
格隆汇8月30日丨中国先锋医药(01345.HK)公布,截至2019年6月30日止6个月,公司收益达6.2亿元人民币,期间纯利达9820万元,每股盈利0.08元。
期间该集团平均毛利率由上年同期的34.9%增加至于报告期内的49.2%。该集团通过提供综合性营销、推广及渠道管理服务销售的药品的毛利率由上年同期的64.3%增加至于报告期内的67.8%,主要由于毛利率较高的部分产品于报告期内销售比例有所增加所致。
作为该公集团的畅销产品之一,凭藉产品的品质优势、良好的市场布局及合理的营销策略,希弗全过去几年一直保持高速增长。报告期内,该集团就销售希弗全实现的收益为人民币171.1百万元,较去年同期增长8.2%。
报告期内,该集团通过提供综合性营销、推广及渠道管理服务销售的医疗器械收益为人民币64.6百万元,较去年同期增加32.4%,占该集团于报告期内收益10.4%。
公司称,随着中国医疗体制改革进入深水区,医药行业正在逐步形成新的生态。传统的研发、审评审批、定价体系正发生深刻的变化,医药市场正在面临重大的结构性调整。总体来看,医药行业内部分化发展将是长期趋势,有明确临床价值、能满足临床需求的治疗性产品将面临更大的发展机遇。该集团将继续围绕产品开发引进、深度挖掘产品营销能力、合作共赢扩大产品市场覆盖、适时通过并购方式充实产业链这几方面,在中国医药行业格局的变化中积极应对,锐意进取,实现未来发展的新蓝图。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.